DK3071697T3 - Adenovirus der udtrykker immuncelle-stimulatorisk(e) receptor agonist(er) - Google Patents

Adenovirus der udtrykker immuncelle-stimulatorisk(e) receptor agonist(er) Download PDF

Info

Publication number
DK3071697T3
DK3071697T3 DK14864921.3T DK14864921T DK3071697T3 DK 3071697 T3 DK3071697 T3 DK 3071697T3 DK 14864921 T DK14864921 T DK 14864921T DK 3071697 T3 DK3071697 T3 DK 3071697T3
Authority
DK
Denmark
Prior art keywords
immuncelle
stimulatory
receptor agonist
adenovirus expressing
adenovirus
Prior art date
Application number
DK14864921.3T
Other languages
English (en)
Inventor
Frank Tufaro
Juan Fueyo-Margareto
Candelaria Gomez-Manzano
W K Alfred Yung
Hong Jiang
Charles Conrad
Original Assignee
Dnatrix Inc
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnatrix Inc, Univ Texas filed Critical Dnatrix Inc
Application granted granted Critical
Publication of DK3071697T3 publication Critical patent/DK3071697T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK14864921.3T 2013-11-22 2014-11-21 Adenovirus der udtrykker immuncelle-stimulatorisk(e) receptor agonist(er) DK3071697T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361907860P 2013-11-22 2013-11-22
PCT/US2014/066920 WO2015077624A1 (en) 2013-11-22 2014-11-21 Adenovirus expressing immune cell stimulatory receptor agonist(s)

Publications (1)

Publication Number Publication Date
DK3071697T3 true DK3071697T3 (da) 2020-01-27

Family

ID=53180213

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14864921.3T DK3071697T3 (da) 2013-11-22 2014-11-21 Adenovirus der udtrykker immuncelle-stimulatorisk(e) receptor agonist(er)

Country Status (11)

Country Link
US (3) US20160289645A1 (da)
EP (2) EP3653714A1 (da)
JP (3) JP2016540505A (da)
KR (1) KR20160137946A (da)
CN (2) CN114317461A (da)
AU (1) AU2014352749A1 (da)
CA (1) CA2931322A1 (da)
DK (1) DK3071697T3 (da)
ES (1) ES2765489T3 (da)
SG (1) SG10201907841UA (da)
WO (1) WO2015077624A1 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6576326B2 (ja) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍溶解性アデノウイルス組成物
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
HUE035875T2 (hu) 2013-10-25 2018-06-28 Psioxus Therapeutics Ltd Heterológ géneket tartalmazó onkolitikus adenovírusok
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
AU2016215175B2 (en) * 2015-02-06 2021-09-16 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
CN107690479B (zh) 2015-04-30 2022-02-18 皮斯奥克斯治疗公司 编码b7蛋白质的溶瘤腺病毒
US10259882B2 (en) 2015-05-07 2019-04-16 Agenus Inc. Anti-OX40 antibodies
JP6954648B2 (ja) * 2015-10-19 2021-10-27 シージー オンコロジー， インコーポレイテッド 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
TW202134282A (zh) 2015-12-02 2021-09-16 美商艾吉納斯公司 抗體和使用彼之方法
MX2018007249A (es) 2015-12-17 2019-05-16 Psioxus Therapeutics Ltd Adenovirus del grupo b que codifica un anticuerpo contra el complejo tcr o fragmento de este.
WO2017118867A1 (en) 2016-01-08 2017-07-13 Replimune Limited Use of an oncolytic virus for the treatment of cancer
KR20180112024A (ko) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN108778301A (zh) 2016-03-10 2018-11-09 永恒生物科技股份有限公司 通过联合疗法来治疗实体瘤或淋巴瘤的方法
WO2017205875A1 (en) * 2016-05-27 2017-11-30 Dnatrix, Inc. Adenovirus and immunomodulator combination therapy
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
PL3293201T3 (pl) * 2016-09-12 2021-06-14 Targovax Oy Łączenie adenowirusa i inhibitorów punktów kontrolnych do leczenia nowotworu
AU2017359467A1 (en) 2016-11-09 2019-05-02 Agenus Inc. Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof
JP2019536468A (ja) 2016-12-12 2019-12-19 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍を標的にする合成アデノウイルスおよびその使用
AU2017375958A1 (en) * 2016-12-12 2019-07-04 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
CN110650745A (zh) * 2016-12-21 2020-01-03 曼珍有限责任公司 武装复制型溶瘤腺病毒
US11298420B2 (en) * 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
CN108338994A (zh) * 2017-01-25 2018-07-31 杭州康万达医药科技有限公司 溶瘤病毒作为用于***和/或癌症的免疫刺激剂的应用
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination
KR20190134786A (ko) 2017-04-14 2019-12-04 콜드 제네시스, 인크. 방광암의 치료 방법
CN109276580B (zh) * 2017-07-21 2021-08-24 厦门大学 一种用于***的病毒
GB2597623A (en) 2017-08-07 2022-02-02 Univ California Platform for generating safe cell therapeutics
CN107952069A (zh) * 2017-11-24 2018-04-24 长春百克生物科技股份公司 重组疫苗及其应用
CN109985241A (zh) * 2017-12-29 2019-07-09 广州威溶特医药科技有限公司 Cdk抑制剂和溶瘤病毒在制备抗肿瘤药物的应用
US20210015878A1 (en) * 2018-03-28 2021-01-21 Epicentrx, Inc. Personalized cancer vaccines
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
EP3850103A4 (en) 2018-09-15 2022-06-22 Memorial Sloan Kettering Cancer Center RECOMBINANT POXVIRUS FOR CANCER IMMUNOTHERAPY
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 ***新抗原及其用途
EP3927833A4 (en) * 2019-02-21 2022-11-30 Unleash Immuno Oncolytics, Inc. ONCOLYTIC ADENOVIRAL VECTOR AND METHODS OF USE
BR112022001912A2 (pt) 2019-08-05 2022-04-19 Mesoblast Int Sarl Composições celulares compreendendo vetores virais e métodos de tratamento
CN110859968A (zh) * 2019-11-21 2020-03-06 四川安可康生物医药有限公司 激活对肿瘤的***免疫反应的基因生物药物
EP4164683A1 (en) * 2020-06-10 2023-04-19 Richard Lowenthal Engineered adenovirus vectors and uses thereof
JP2023537103A (ja) 2020-08-10 2023-08-30 メゾブラスト・インターナショナル・エスアーエールエル 細胞組成物及び治療方法
JP2023031503A (ja) 2021-08-25 2023-03-09 三菱重工航空エンジン株式会社 燃焼器パネル、及びガスタービン用燃焼器
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5981725A (en) 1989-09-08 1999-11-09 The Johns Hopkins Univiersity Structural alterations of the EGF receptor gene in human tumors
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
WO1996033280A1 (en) 1995-04-17 1996-10-24 Board Of Regents, The University Of Texas System An adenovirus helper-virus system
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
WO1999028349A2 (en) * 1997-12-02 1999-06-10 Medarex, Inc. CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US7368527B2 (en) * 1999-03-12 2008-05-06 Human Genome Sciences, Inc. HADDE71 polypeptides
US20030138405A1 (en) 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
WO2003064666A1 (en) * 2002-02-01 2003-08-07 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
ES2295639T3 (es) 2002-06-13 2008-04-16 Crucell Holland B.V. Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
CA2530172A1 (en) 2003-06-27 2005-02-10 Abgenix, Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
JP2008531481A (ja) * 2005-02-08 2008-08-14 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム 癌の治療のための、ｍｄａ−７を含む組成物および方法
WO2006121810A2 (en) 2005-05-06 2006-11-16 Providence Health System Trimeric ox40-immunoglobulin fusion protein and methods of use
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
ES2304281B1 (es) * 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
SI2079760T1 (sl) 2006-12-27 2016-11-30 Emory University Sestavki in metode za zdravljenje okužb
EA201170375A1 (ru) 2008-08-25 2012-03-30 Эмплиммьюн, Инк. Антагонисты pd-1 и способы их применения
KR101629071B1 (ko) * 2008-10-08 2016-06-09 인트렉손 코포레이션 다수의 면역조절자를 발현하는 조작된 세포 및 그 용도
HRP20240240T1 (hr) 2008-12-09 2024-04-26 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
MX339964B (es) * 2010-08-23 2016-06-17 Board Of Regents The Univ Of Texas System * Anticuerpos anti-ox40 y metodos para usarlos.
CA2812096A1 (en) * 2010-09-24 2012-03-29 Oncos Therapeutics Oy Adenoviral vectors and methods and uses related thereto
EP3187603A1 (en) * 2011-02-17 2017-07-05 Arconic Inc. 2xxx series aluminum lithium alloys
EA201301173A1 (ru) * 2011-04-15 2015-08-31 Дженелюкс Корпорейшн Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования
US10238698B2 (en) * 2012-01-25 2019-03-26 Dnatrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
ES2759785T3 (es) * 2012-02-02 2020-05-12 Univ Texas Adenovirus que expresan antígenos oncógenos heterólogos

Also Published As

Publication number Publication date
ES2765489T3 (es) 2020-06-09
US20190093085A1 (en) 2019-03-28
EP3071697A1 (en) 2016-09-28
EP3071697A4 (en) 2017-05-17
CN114317461A (zh) 2022-04-12
SG10201907841UA (en) 2019-10-30
JP2020048582A (ja) 2020-04-02
CA2931322A1 (en) 2015-05-28
EP3071697B1 (en) 2019-10-16
US20210301264A1 (en) 2021-09-30
CN106029889A (zh) 2016-10-12
US20160289645A1 (en) 2016-10-06
WO2015077624A1 (en) 2015-05-28
EP3653714A1 (en) 2020-05-20
AU2014352749A1 (en) 2016-06-09
KR20160137946A (ko) 2016-12-02
JP2016540505A (ja) 2016-12-28
JP2021137029A (ja) 2021-09-16

Similar Documents

Publication Publication Date Title
DK3071697T3 (da) Adenovirus der udtrykker immuncelle-stimulatorisk(e) receptor agonist(er)
DK3368060T3 (da) Glugacon-receptor-agonister
DK3848027T3 (da) Octahydro-kondenserede azadecalinglucocorticoidreceptormodulatorer
DK3578188T3 (da) T-cellereceptorer
DK3039148T3 (da) Transduktionsbuffer
FR3000544B1 (fr) Dispositif de pesage multi-fonction
EP3077419A4 (en) G-protein coupled receptor agonists and methods
FI10595U1 (fi) Testausadapteri
DK2976637T3 (da) Prøveapparat
DK2861209T3 (da) Somatostatinreceptoragonistformuleringer
DK2877173T3 (da) Antagonister / inverse agonister til cannabinoidreceptorer
IL245948B (en) 5–ht4 indazole compounds as receptor agonists
IL243730A0 (en) Vasopressin-2 receptor agonists
HK1217483A1 (zh) 作爲 受體激動劑的 -氨基-喹啉- -甲酰胺衍生物
DK3074384T3 (da) Amidderivater til gpr119-agonist
DK2964206T3 (da) Beta-2-adrenerg receptoragonist til forbedring af farvetilpasning af hudar
GB201312010D0 (en) Receptor Agonists
DE102014005283A8 (de) Längenmessvorrichtung
FR3014440B1 (fr) Polypeptides entomotoxiques
DE102014100152A8 (de) Kontrollwaagengestell
GB201309249D0 (en) Content optimisation using 3G measurements
ES1079034Y (es) Estribo con ala
TH1601000316A (th) อะโกนิสต์ของตัวรับวาโซเพรสซิน-2
GB201304105D0 (en) Agonist
ES1091481Y (es) Palillo con banderola perfeccionado